Sabra Health Care REIT Inc.

▲ Bull Case

• ◆SHOP NOI +14.4% YoY is the most compelling healthcare REIT metric in the sector — above comparable Ventas metrics — yet the market still classifies SBRA as an SNF REIT. When SHOP reaches 40% of portfolio and analysts re-classify, the comp group shifts from OHI (12-13x P/AFFO) to VTR (22-25x). Even partial convergence to 16-18x creates $8-12/share in additional value, and at 16x FY2028E AFFO of $1.90, fair value reaches $30.40/share.
• ◆Structural senior housing supply shortage provides a 3-5 year durable tailwind: construction is at 40-year lows, net absorption runs 3x supply growth, industry occupancy hit 89.1% in Q4 2025, and the 80+ population grows +48% by 2030. This supply/demand imbalance supports continued SHOP NOI compounding independent of macro conditions.
• ◆Acquisition pipeline exceeding $1B at 8.3% yields — 120-180bps above sector average — guarantees AFFO compounding of 5-10%/yr. At $1.57-$1.90 AFFO/share through FY2028E, the company trades at 10.5x forward AFFO with zero multiple expansion assumed. CEO Matros's $52M personal stake and 16-year operator relationship network are the highest insider alignment signal in the coverage batch and the primary source of proprietary deal flow.

▼ Bear Case

• ◆SHOP multiple re-rating is a 2-3 year story requiring multiple consecutive quarters of 90%+ occupancy, AFFO beats, and dividend raises before analysts re-classify SBRA away from the SNF REIT peer group. The re-rating is not guaranteed even as operational evidence accumulates, and the 2022 dividend cut overhang continues to suppress the multiple and income investor confidence.
• ◆SNF operator credit risk remains the primary tail risk: ~55-60% of revenue derives from triple-net SNF leases, and the top 2-3 operators collectively represent 30-40% of SNF revenue. A major SNF operator default (>10% ABR) would create 12-18 months of revenue disruption and force a formal thesis review, with no single operator above ~20% ABR providing only modest diversification.
• ◆FY2025 AFFO growth of only +3.5% was disappointing versus the historical 8-10% pace, and cap rate compression threatens the accretion engine: the sector deployed $25.28B in FY2025 (2.5x FY2024). If proprietary yield advantages compress from 8.3% toward sector average of 6.5-7%, AFFO growth slows to 3-5%/yr, invalidating the re-rating timeline and making the 40% SHOP target arrive too late for near-term multiple expansion.

“The central debate is whether SBRA should be valued on a SNF REIT framework (~12-13x P/AFFO, OHI comp group) or a SHOP REIT framework (~22-25x, Ventas comp group). Bulls argue that +14.4% SHOP SS NOI growth and an accelerating pivot toward 40% SHOP constitute clear evidence of a mid-transition SHOP platform deserving 16-18x P/AFFO, implying $8-12/share of undervalued upside even before full re-classification. Bears counter that SBRA remains 55-60% SNF by revenue, the 2022 dividend cut created a lasting credibility discount, FY2025 AFFO growth (+3.5%) was weak, and there is no guarantee the market re-rates the stock until SHOP eclipses SNF as the primary earnings driver — a milestone potentially 2+ years away. A secondary debate concerns capital allocation: the aggressive $1B+/yr deployment pace (Q1 2026 alone >$400M) is AFFO-accretive at 8.3% yields but is increasing leverage toward 6.5x Net Debt/EBITDA, and the sustainability of proprietary yield advantages versus a sector experiencing 2.5x higher transaction volumes is unresolved. The dividend raise timing is a live catalyst — at 77% payout ratio and accelerating AFFO, the capacity clearly exists, but management has not committed to a timeline.”

• ◆SHOP same-store occupancy crossing 90% (expected Q3-Q4 2026) — primary re-rating trigger enabling institutional re-classification toward SHOP comp group
• ◆First dividend raise since the 2022 cut (Q2-Q3 2026 likely) — 77% payout ratio + accelerating AFFO = capacity exists; raise of $0.03+/quarter signals management confidence and triggers income investor re-pricing
• ◆FY2026 AFFO guidance raised above $1.59 ceiling — Q1 2026 $0.39/share run-rate at guidance floor; beat narrows the P/AFFO discount
• ◆SHOP reaching 35-40% of portfolio (FY2026-FY2027) — milestone makes analyst re-classification from SNF to SHOP comp group defensible
• ◆Matros succession plan announcement with 18+ month transition runway — resolves key-person risk and sustains acquisition yield advantage credibility
• ◆Continued dividend growth compounding — each raise moves GGM implied growth from 2.6% toward 4%+, creating incremental price re-rating

• ◆SHOP same-store occupancy falling below 85% for two consecutive quarters — would signal structural supply or labor adverse event; trigger: reduce 30%
• ◆Single SNF operator default representing >10% of ABR — top 1-2 relationships; would create 12-18 months revenue disruption; trigger: reduce 40%
• ◆Net Debt/EBITDA rising above 7.5x LTM — would trigger S&P BBB- negative watch, raise borrowing costs 150-200bps, and impair acquisition engine; trigger: reduce 35%
• ◆CEO Matros departure without 18+ month structured transition — loses relationship-based deal sourcing advantage (8.3% vs. 6-7% sector yield); trigger: reduce 25% and apply 2x turn P/AFFO discount
• ◆FY2027E AFFO guidance below $1.60/share when issued (February 2027) — signals thesis running 12-18 months behind schedule; trigger: reduce 20% and revise to bear case trajectory
• ◆Cap rate compression toward sector average 6.5-7% from proprietary 8.3% — would slow AFFO compounding to 3-5%/yr and delay the 40% SHOP target